1 / 1

APPRAISE

APPRAISE. ISTH major or CRNM bleeding: 7.9% for 10 mg apixaban, 5.7% for 5 mg apixaban, 3% for placebo Death, MI, recurrent ischemia, or stroke: 6.0%, 7.6%, 8.7% (p = 0.07 for high dose vs. placebo and p = 0.21 for low dose vs. placebo), respectively.

fruma
Télécharger la présentation

APPRAISE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. APPRAISE ISTH major or CRNM bleeding: 7.9% for 10 mg apixaban, 5.7% for 5 mg apixaban, 3% for placebo Death, MI, recurrent ischemia, or stroke: 6.0%, 7.6%, 8.7% (p = 0.07 for high dose vs. placebo and p = 0.21 for low dose vs. placebo), respectively Trial design:Patients recovering from an ACS were randomized to apixaban 10 mg daily (n = 318), apixaban 2.5 mg twice daily (n = 317), or placebo (n = 611). Study medications were administered for 6 months. Results (p = 0.005 for high dose vs. placebo) (p = 0.09 for low dose vs. placebo) 7.9 5.7 % Conclusions 3.0 • This dose-finding study reveals that bleeding is increased among patients with a recent ACS with higher doses of apixaban compared with placebo • Although this study was not powered for efficacy, adverse events appeared to be lowest with 10 mg apixaban ISTH major or CRNM bleeding Apixaban 10 mg Apixaban 5 mg Placebo APPRAISE Investigators. Circulation 2009;May 26:[Epub]

More Related